ESR1 and breast carcinoma: Even though Beta hCG cannot be used as tumour marker, its high significance with respect to TNM staging and ki67 tumour marker can be used to prognosticate the severity of breast carcinoma in women with palpable breast malignancies and to predict the outcome of the disease in association with other tumour markers such as ER, PR and HER2neu.